secwatch.observer — SEC 8-K summary
======================================

Issuer:     Iterum Therapeutics plc (ITRMF)
CIK:        0001659323
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0000950170-25-035943
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Iterum Therapeutics appoints Joseph Whalen to board; David Kelly named Chairman
-------------------------------------------------------------------------------

- Joseph J. Whalen appointed as Class III director effective March 10, 2025; term expires at 2027 AGM.
- Whalen joins Audit and Compensation Committees; receives annual cash retainers of $35,000 (board), $7,500 (audit), $6,000 (compensation).
- David Kelly appointed Chairman of the Board effective March 10, 2025, after Ronald Hunt resigned on February 14, 2025.
- Whalen's appointment restores Audit Committee to three independent members, regaining Nasdaq Listing Rule 5605(c)(2)(A) compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659323/000095017025035943/0000950170-25-035943-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659323/000095017025035943/itrm-20250307.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-035943

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer